OSHA

Occupational Health and Safety Administration

OSI-211

liposomal lurtotecan drug manufactured by

OSI

Pharmaceuticals

P13K

phosphatidylinositol 3-kinase

PEG

polyethylene glycol

PEG-IFNα2a/-IFNα2b

pegylated interferon α-2a/interferon α-2b

PEG-L-asparaginase

polyethylene glycol conjugated asparaginase

PGA-paclitaxel

polyglutamic acid conjugated paclitaxel

PHPMA-doxorubicin

poly(2-hydroxypropyl methacrylate) conjugated doxorubicin

PK

pharmacokinetics

PK1

N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin

PK2

N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer backbone and pendant doxorubicin (DOX) linked via a Gly-Phe-Leu-Gly peptide spacer

PLD-E1A

pegylated liposomal doxorubicin–linked E1A (an adenoviral oncogene) plasmid DNA

PLGA

polylactic-co-glycolic acid

PRINT

particle replication in non-wetting templates

PSA

prostate specific antigen

RBC

red blood cell

RES

reticuloendothelial system

RNA

ribonucleic acid

RNAi

RNA interference

SGN-15

cBR96-doxorubicin immunoconjugate, SGN stands for Seattle Genetics Inc.

siRNA

short interfering RNA or silencing RNA

SPARC

secreted protein, acidic and rich in cysteine

SPI-77

sterically stabilised liposomal cisplatin

TGF-β

transforming growth factor β

TNF

tumor necrosis factor

TNF-γ

tumor necrosis factor γ

UK

United Kingdom

WBC

white blood cell



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement